Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine - Lin, Jiang-Tao; Zhang, Jian-San; Su, Nan; Xu, Jian-Guo; Wang, Nan; Chen, Jiang-Ting; Chen, Xin; Liu, Yu-Xuan; Gao, Hong; Jia, Yu-Ping; Liu, Yan; Sun, Rui-Hua; et al. (Antiviral therapy, 2007)
Keywords: Adult; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antibodies, Viral - biosynthesis; Antibodies, Viral - immunology; Antiviral agents; Biological and medical sciences; Double-Blind Method; Female; Human viral diseases; Humans; Infectious diseases; Male; Medical sciences; Neutralization Tests; Pharmacology. Drug treatments; SARS Virus - immunology; Severe Acute Respiratory Syndrome - immunology; Severe Acute Respiratory Syndrome - therapy; Severe Acute Respiratory Syndrome - virology; Vaccination; Vaccines, Inactivated - adverse effects; Vaccines, Inactivated - immunology; Viral diseases; Viral diseases of the respiratory system and ent viral diseases; Viral Vaccines - adverse effects; Viral Vaccines - immunology; Human; Lung disease; Respiratory disease; Toxicity; Severe acute respiratory syndrome; Vaccine; Infection; Virus; Prevention; Immunoprophylaxis; Coronavirus; Immunogenicity; Viral disease; Phase I trial; Coronaviridae; Nidovirales